Finance

Lists
Q2 2026 earnings • released • EPS beat +26.13%
See results
AVIR:NASDAQ
Atea Pharmaceuticals Inc
$5.12
+0.99%
(+0.050) 1D
$5.01
-2.15% (-0.11)
After hours
Closed: Aug 14, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVIR...
Open
$5.03
High
$5.23
Low
$4.99
Mkt. cap
410.65M
Avg. vol.
356.95K
Volume
250.01K
52-wk high
$6.45
52-wk low
$2.78
EPS
-$2.12
Beta
0.30
Shares outstanding
80.20M
No. of employees
55
Open
$5.03
High
$5.23
Low
$4.99
Mkt. cap
410.65M
Avg. vol.
356.95K
Volume
250.01K
52-wk high
$6.45
52-wk low
$2.78
EPS
-$2.12
Beta
0.30
Shares outstanding
80.20M
No. of employees
55
About Atea Pharmaceuticals Inc
CEO-
Employees55
Founded2012
HeadquartersBoston, Massachusetts, United States
SectorPharmaceutical industry
Websiteateapharma.com
Analyst ratings
Based on 2 analysts giving stock ratings to AVIR in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for AVIR in the last 3 months.
Highest
Current $5.12
$7.00 (+36.72%)
Average
$7.00 (+36.72%)
Lowest
$7.00 (+36.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Hold
Reiterated
$7.00
+36.7%
08/13/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
08/12/2026
Umer Raffat
Evercore ISI
Buy
Maintained
$10.00
+95.3%
03/09/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.41 / -$0.56
+26.13%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
38.23M
47.60M
41.13M
28.15M
Cost of revenue
38.23M
47.60M
41.13M
28.15M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.22M
7.12M
6.87M
6.95M
Operating expense
7.22M
7.12M
6.87M
6.95M
Total operating expenses
45.45M
54.71M
48.01M
35.10M
Operating income
-45.45M
-54.71M
-48.01M
-35.10M
Other non operating income
-
-
-
-
EBT including unusual items
-41.85M
-51.64M
-45.39M
-32.91M
EBT excluding unusual items
-41.74M
-51.41M
-45.39M
-32.91M
Income tax expense
196.00K
-6.77M
50.00K
24.00K
Effective tax rate
-0.47%
13.11%
-0.11%
-0.07%
Other operating expenses
-
-
-
-
Net income
-42.05M
-44.87M
-45.44M
-32.93M
Net profit margin
-
-
-
-
Earnings per share
-0.53
-0.57
-0.57
-0.41
Interest and investment income
3.71M
3.30M
2.62M
2.19M
Interest expense
-
-
-
-
Net interest expenses
3.71M
3.30M
2.62M
2.19M
Depreciation and amortization charges
-
-
-
-
EBITDA
-45.35M
-54.61M
-47.90M
-35.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps